A new clinical trial at Kingston Health Sciences Centre could mark a turning point in how anxiety is treated in Canada.

For the first time in Canada, researchers are studying the effects of micro-dose psilocybin , the active ingredient found in magic mushrooms, on people living with generalized anxiety disorder (GAD).

“There are significant unmet needs among people living with generalized anxiety disorder, and they are seeking effective, well-tolerated treatments,” said Dr. Claudio Soares, principal investigator and attending physician in KHSC’s Mental Health and Addiction program.

Psilocybin is being tested for its potential to reduce anxiety without causing hallucinations.

“Not everybody has access to treatment, but also not everybody can tolerate medications for anxiety,” said S

See Full Page